Enhanced CGM for Diabetes

This trial aims to make continuous glucose monitoring (CGM), a tool that tracks blood sugar levels in real-time, more accessible in primary care settings for people with diabetes. The researchers seek to determine if their program, SPARK-CGM, can enable more primary care providers to prescribe CGM devices to their patients. They anticipate that this will lead to better blood sugar control and an improved quality of life for people with diabetes. Suitable participants include adults with diabetes who receive primary care at Montefiore Medical Center and are on insulin therapy. As an unphased trial, this study offers a unique opportunity to contribute to the wider availability of CGM, potentially enhancing diabetes management for many.

The trial information does not specify whether you need to stop taking your current medications. It focuses on using continuous glucose monitoring for diabetes management.

Past research has raised safety concerns about some continuous glucose monitors (CGMs). Abbott identified that certain CGM sensors were linked to seven deaths and over 700 serious injuries due to incorrect blood sugar readings. These issues arose mainly because the sensors displayed falsely low blood sugar levels, posing a danger. Consequently, about 3 million sensors required replacement.

Researchers are excited about the Enhanced CGM for Diabetes trial because it focuses on improving the use and understanding of continuous glucose monitors (CGM) in clinical settings. Unlike standard care, which often involves periodic glucose checks and insulin adjustments, this trial aims to streamline CGM integration into clinics. Key features include developing clinic workflows for CGM prescribing, educating providers on interpreting CGM data, and training staff to support CGM use. This approach could lead to more personalized and effective diabetes management, improving patient outcomes and clinic efficiency.

Research has shown that continuous glucose monitoring (CGM) can significantly help people with diabetes manage their blood sugar levels. Studies indicate that CGM lowers average blood sugar levels (HbA1c), reduces episodes of severe hypoglycemia, and increases the time spent in the target blood sugar range. For example, one study found that real-time CGM increased time in the target range by about 5.63% and reduced low blood sugar episodes by 1.28%. These findings suggest that CGM can enhance blood sugar control and improve the overall quality of life for individuals with type 1 and type 2 diabetes. In this trial, clinics will implement the SPARK-CGM system during the intervention phase to assess its impact on diabetes management.⁶⁷⁸⁹¹⁰